Bristol Pushes Pedal To Metal In Immuno-Oncology Combo Testing

Bristol's early development lead exec Mike Burgess explains how the company is embracing adaptive trial design to rapidly test combinations of immuno-oncology drugs old and new, plus targeted agents.